

THE GENERAL ASSEMBLY OF PENNSYLVANIA

HOUSE BILL

No. 1217 Session of 2013

INTRODUCED BY STERN, MILLARD, PICKETT, SCHLOSSBERG, R. BROWN, HEFFLEY, GRELL, V. BROWN, D. COSTA, BAKER, MARSHALL, HICKERNELL, MAJOR, MOUL, GODSHALL, OBERLANDER, CLYMER, SWANGER, MILLER, KORTZ, MARSICO, GINGRICH, KAUFFMAN, CALTAGIRONE, ROCK, WATSON, QUINN, LAWRENCE AND HESS, APRIL 17, 2013

AS REPORTED FROM COMMITTEE ON JUDICIARY, HOUSE OF REPRESENTATIVES, AS AMENDED, APRIL 23, 2013

AN ACT

1 Amending the act of April 14, 1972 (P.L.233, No.64), entitled
2 "An act relating to the manufacture, sale and possession of
3 controlled substances, other drugs, devices and cosmetics;
4 conferring powers on the courts and the secretary and
5 Department of Health, and a newly created Pennsylvania Drug,
6 Device and Cosmetic Board; establishing schedules of
7 controlled substances; providing penalties; requiring
8 registration of persons engaged in the drug trade and for the
9 revocation or suspension of certain licenses and
10 registrations; and repealing an act," further providing for
11 schedules of controlled substances.

12 The General Assembly of the Commonwealth of Pennsylvania
13 hereby enacts as follows:

14 Section 1. ~~Section 4(1)(vii) of the act of April 14, 1972~~ <--
15 ~~(P.L.233, No.64), known as The Controlled Substance, Drug,~~
16 ~~Device and Cosmetic Act, amended June 20, 2011 (P.L.86, No.7),~~
17 ~~is amended and the paragraph is amended by adding a subparagraph~~
18 ~~to read:~~

19 Section 4. ~~Schedules of Controlled Substances. The~~
20 ~~following schedules include the controlled substances listed or~~

1 ~~to be listed by whatever official name, common or usual name,~~
2 ~~chemical name, or trade name designated.~~

3 ~~(1) Schedule I In determining that a substance comes within~~
4 ~~this schedule, the secretary shall find: a high potential for~~
5 ~~abuse, no currently accepted medical use in the United States,~~
6 ~~and a lack of accepted safety for use under medical supervision.~~
7 ~~The following controlled substances are included in this~~
8 ~~schedule:~~

9 ~~* * *~~

10 ~~(iii.1) Any compound, except bupropion or compounds listed~~
11 ~~under a different schedule, or compounds used within legitimate~~
12 ~~and approved medical research, structurally derived from 2-~~
13 ~~aminopropan-1-one by substitution at the 1 position with phenyl,~~
14 ~~naphthyl or thiophenen ring systems, whether or not the compound~~
15 ~~is further modified in any of the following ways:~~

16 ~~1. By substitution in the ring system to any extent with~~
17 ~~alkyl, alkylendioxy, alkoxy, haloalkyl, hydroxyl or halide~~
18 ~~substituents whether or not further substituted in the ring~~
19 ~~system by one or more other univalent substituents.~~

20 ~~2. By substitution at the 3 position with an acyclic alkyl~~
21 ~~substituent.~~

22 ~~3. By substitution at the 2 amino nitrogen atom with alkyl,~~
23 ~~dialkyl, benzyl or methoxybenzyl groups.~~

24 ~~4. By inclusion of the 2 amino nitrogen atom in a cyclic~~
25 ~~structure.~~

26 ~~* * *~~

27 ~~(vii) [Synthetic cannabinoids or any material, compound,~~
28 ~~mixture or preparation which contains any quantity of the~~
29 ~~following substances, including their analogues, congeners,~~
30 ~~homologues, isomers, salts and salts of analogues, congeners,~~

1 homologues and isomers, as follows:

2 1. ~~CP 47,497 and homologues, 2 [(1R,3S) 3-~~

3 ~~hydroxycyclohexyl] 5 (2-methyloctan-2-yl)phenol).~~

4 2. ~~HU 210, [(6aR,10aR) 9 (hydroxymethyl) 6,6-dimethyl 3 (2-~~

5 ~~methyloctan-2-yl) 6a,7,10, 10a-tetrahydrobenzo[c]chromen-1-~~

6 ~~ol)]).~~

7 3. ~~HU 211, (dexanabinol, (6aS,10aS) 9 (hydroxymethyl) 6,6-~~

8 ~~dimethyl 3 (2-methyloctan-2-yl) 6a,7,10,10a-~~

9 ~~tetrahydrobenzo[c]chromen-1-ol).~~

10 4. ~~JWH 018, 1-pentyl 3 (1-naphthoyl)indole.~~

11 5. ~~JWH 019, 1-hexyl 3 (1-naphthoyl)indole.~~

12 6. ~~JWH 073, 1-butyl 3 (1-naphthoyl)indole.~~

13 7. ~~JWH 200, (1-(2-morpholin-4-ylethyl)indol-3-yl)-~~

14 ~~naphthalen-1-ylmethanone.~~

15 8. ~~JWH 250, 1-pentyl 3 (2-methoxyphenylacetyl)indole.]~~

16 ~~Synthetic cannabinoids including any material, compound, mixture~~

17 ~~or preparation that is not listed as a controlled substance in~~

18 ~~Schedule I through V, is not a Federal Food and Drug~~

19 ~~Administration approved drug or used within legitimate and~~

20 ~~approved medical research and which contains any quantity of the~~

21 ~~following substances, their salts, isomers, whether optical~~

22 ~~positional or geometric, analogues, homologues and salts of~~

23 ~~isomers, analogues and homologues, unless specifically excepted,~~

24 ~~whenever the existence of these salts, isomers, analogues,~~

25 ~~homologues and salts of isomers, analogues and homologues if~~

26 ~~possible within the specific chemical designation:~~

27 ~~1. Tetrahydrocannabinols or tetrahydrocannabinols which is~~

28 ~~naturally contained in a plant of the genus cannabis as well as~~

29 ~~synthetic equivalents of the substances contained in the plant~~

30 ~~or in the resinous extractives of Cannabis or synthetic~~

~~1 substances, derivatives and their isomers with similar chemical~~
~~2 structure and or pharmacological activity such as the following:~~

~~3 (A) Delta 1 cis or trans tetrahydrocannabinol and their~~
~~4 optical isomers.~~

~~5 (B) Delta 6 cis or trans tetrahydrocannabinol and their~~
~~6 optical isomers.~~

~~7 (C) Delta 3, 4 cis or their trans tetrahydrocannabinol and~~
~~8 their optical isomers.~~

~~9 2. Naphthoxylindoles or any compound containing a 3-(1~~
~~10 naphthoyl) indole structure with substitution at the nitrogen~~
~~11 atom of the indole ring by an alkyl, haloalkyl, cyanoalkyl,~~
~~12 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1-(N methyl 2-~~
~~13 piperidinyl) methyl, 2-(4 morpholinyl) ethyl, 1-(N methyl 2-~~
~~14 pyrrolidinyl) methyl, 1-(N methyl 3 morpholinyl) methyl or~~
~~15 (tetrahydropyran 4 yl) methyl group, whether or not further~~
~~16 substituted in the indole ring to any extent and whether or not~~
~~17 substituted in the naphthyl ring to any extent. This shall~~
~~18 include the following:~~

~~19 (A) JWH 015.~~

~~20 (B) JWH 019.~~

~~21 (C) JWH 073.~~

~~22 (D) JWH 081.~~

~~23 (E) JWH 122.~~

~~24 (F) JWH 200.~~

~~25 (G) JWH 210.~~

~~26 (H) JWH 398.~~

~~27 (I) AM2201.~~

~~28 (J) WIN 55 212.~~

~~29 3. Naphylmethylindoles or any compound containing a 1H-~~
~~30 indol 3 yl (1 naphthyl) methane methane structure with a~~

1 ~~substitution at the nitrogen atom of the indole ring by an alkyl,~~
2 ~~haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,~~
3 ~~cycloalkylethyl, 1 (N methyl 2 piperidinyl) methyl, 2 (4-~~
4 ~~morpholinyl) ethyl, 1 (N methyl 2 pyrrolidinyl) methyl, 1 (N-~~
5 ~~methyl 3 morpholinyl) methyl or (tetrahydropyran 4 yl) methyl~~
6 ~~group, whether or not further substituted in the indole ring to~~
7 ~~any extent and whether or not substituted in the naphthyl ring~~
8 ~~to any extent. This shall include JWH 175 and JWH 184.~~

9 ~~4. Naphthoylpyrroles or any compound containing a 3 (1-~~
10 ~~naphthoyl) pyrrole structure with substitution at the nitrogen~~
11 ~~atom of the pyrrole ring by alkyl, haloalkyl, cyanoalkyl,~~
12 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 (N methyl 2-~~
13 ~~piperidinyl) methyl, 2 (4 morpholinyl) ethyl, 1 (N methyl 2-~~
14 ~~pyrrolidinyl) methyl, 1 (N methyl 3 morpholinyl) methyl or~~
15 ~~(tetrahydropyran 4 yl) methyl group, whether or not further~~
16 ~~substituted in the pyrrole ring to any extent and whether or not~~
17 ~~substituted in the naphthyl ring to any extent. This shall~~
18 ~~include JWH 307.~~

19 ~~5. Naphthylmethylindenes or any compound containing a~~
20 ~~naphthylideneindene structure with substitution at the 3-~~
21 ~~position of the indene ring by an alkyl, haloalkyl, cyanoalkyl,~~
22 ~~alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 (N methyl 2-~~
23 ~~piperidinyl) methyl, 2 (4 morpholinyl) ethyl, 1 (N methyl 2-~~
24 ~~pyrrolidinyl) methyl, 1 (N methyl 3 morpholinyl) methyl or~~
25 ~~(tetrahydropyran 4 yl) methyl group, whether or not further~~
26 ~~substituted in the indene ring to any extent and whether or not~~
27 ~~substituted in the naphthyl ring to any extent. This shall~~
28 ~~include JWH 176.~~

29 ~~6. Phenylacetylindoles or any compound containing a 3-~~
30 ~~phenylacetylindole structure with substitution at the nitrogen~~

~~1 atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,
2 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 (N methyl 2-
3 piperidinyl) methyl, 2 (4 morpholinyl) ethyl, 1 (N methyl 2-
4 pyrrolidinyl) methyl, 1 (N methyl 3 morpholinyl) methyl or
5 (tetrahydropyan 4 yl) methyl group, whether or not further
6 substituted in the indole ring to any extent and whether or not
7 substituted in the phenyl ring to any extent. This shall include
8 the following:~~

~~9 (A) RCS 8 or SR 18.~~

~~10 (B) JWH 250.~~

~~11 (C) JWH 203.~~

~~12 (D) JWH 251.~~

~~13 (E) JWH 302.~~

~~14 7. Cyclohexylphenols or any compound containing a 2 (3-
15 hydroxycyclohexyl) phenol structure with a substitution at the
16 5 position of the phenolic ring by alkyl, haloalkyl, cyanoalkyl,
17 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 (N methyl 2-
18 piperidinyl) methyl, 2 (4 morpholinyl) ethyl, 1 (N methyl 2-
19 pyrrolidinyl) methyl, 1 (N methyl 3 morpholinyl) methyl or
20 (tetrahydropyran 4 yl) methyl group, whether or not substituted
21 in the cyclohexyl ring to any extent. This shall include the
22 following:~~

~~23 (A) CP 47, 497 and its homologues and analogs.~~

~~24 (B) Cannabicyclohexanol.~~

~~25 (C) CP 55, 940.~~

~~26 8. Benzoylindoles or any compound containing a 3 (benzoyl)-
27 indole structure with substitution at the nitrogen atom of the
28 indole ring by alkyl, haloalkyl, cyanoalkyl, alkenyl,
29 cycloalkylmethyl, cycloalkylethyl, 1 (N methyl 2 piperidinyl)-
30 methyl, 2 (4 morpholinyl) ethyl, 1 (N methyl 2 pyrrolidinyl)-~~

~~1 methyl, 1 (N methyl 3 morpholinyl) methyl or (tetrahydropyran-~~
~~2 4-yl) methyl group, whether or not further substituted in the~~
~~3 indole ring to any extent and whether or not substituted in the~~
~~4 phenyl ring to any extent. This shall include the following:~~

~~5 (A) Am 694.~~

~~6 (B) Pravadoline WIN 48098.~~

~~7 (C) RCS 4.~~

~~8 (D) AM 679.~~

~~9 9. [2,3 Dihydro 5 methyl 3 (4 morpholinylmethyl) pyrrolo-~~
~~10 [1,2,3-de] 1,4 benzoxazin 6-yl] 1 naphthalenymethanone. This~~
~~11 shall include WIN 55, 212-2.~~

~~12 10. (6aR,10aR) 9 (hydroxymethyl) 6,6 dimethyl 3(2-~~
~~13 methyloctan-2-yl) 6a,7,10,10a tetrahydrobenzo [c]chromen-1-~~
~~14 old 7370. This shall include HU 210 and HU 211.~~

~~15 11. Adamantoylindoles or any compound containing a 3 (-~~
~~16 adamantoyl) indole structure with substitution at the nitrogen~~
~~17 atom of the indole ring by alkyl, haloalkyl, cyanoalkyl,~~
~~18 alkenyl, cycloalkylmethyl, cycloalkylethyl, 1 (N methyl 2-~~
~~19 piperidinyl) methyl, 2 (4 morpholinyl) ethyl, 1 (N methyl 2-~~
~~20 pyrrolidinyl) methyl, 1 (N methyl 3 morpholinyl) methyl or~~
~~21 (tetrahydropyran 4-yl) methyl group, whether or not further~~
~~22 substituted in the adamantyl ring system of any extent. This~~
~~23 shall include AM 1248.~~

~~24 12. Tetramethylcyclopropanoylindoles or any compound~~
~~25 containing a 3-tetramethylcyclopropylindole structure with~~
~~26 substitution at the nitrogen atom of the indole ring by analkyl,~~
~~27 haloalkyl, cyanoalkyl, alkenyl, cycloalkylmethyl,~~
~~28 cycloalkylethyl, 1 (N methyl 2 piperidinyl) methyl, 2 (4-~~
~~29 morpholinyl) ethyl, 1 (N methyl 2 pyrrolidinyl) methyl, 1 (N-~~
~~30 methyl 3 morpholinyl) methyl or (tetrahydropyran 4-yl) methyl~~

1 ~~group whether or not further substituted in the indole ring to~~
2 ~~any extent and whether or not substituted in the~~
3 ~~tetramethylcyclopropanoyl ring to any extent. This shall include~~
4 ~~UR 144.~~

5 ~~13. Any other synthetic chemical compound that is a~~
6 ~~cannabinoid receptor agonist and mimics the pharmacological~~
7 ~~effect of the naturally occurring cannabinoids that is not~~
8 ~~listed in Schedules II through V, not an Federal Food and Drug~~
9 ~~Administration approved drug or used within legitimate, approved~~
10 ~~medical research.~~

11 * * *

12 Section 2. ~~This act shall take effect in 60 days.~~

13 SECTION 1. SECTION 4(1)(VII) OF THE ACT OF APRIL 14, 1972 <--
14 (P.L.233, NO.64), KNOWN AS THE CONTROLLED SUBSTANCE, DRUG,
15 DEVICE AND COSMETIC ACT, AMENDED JUNE 23, 2011 (P.L.36, NO.7),
16 IS AMENDED AND THE PARAGRAPH IS AMENDED BY ADDING A SUBPARAGRAPH
17 TO READ:

18 SECTION 4. SCHEDULES OF CONTROLLED SUBSTANCES.--THE
19 FOLLOWING SCHEDULES INCLUDE THE CONTROLLED SUBSTANCES LISTED OR
20 TO BE LISTED BY WHATEVER OFFICIAL NAME, COMMON OR USUAL NAME,
21 CHEMICAL NAME, OR TRADE NAME DESIGNATED.

22 (1) SCHEDULE I--IN DETERMINING THAT A SUBSTANCE COMES WITHIN
23 THIS SCHEDULE, THE SECRETARY SHALL FIND: A HIGH POTENTIAL FOR
24 ABUSE, NO CURRENTLY ACCEPTED MEDICAL USE IN THE UNITED STATES,
25 AND A LACK OF ACCEPTED SAFETY FOR USE UNDER MEDICAL SUPERVISION.
26 THE FOLLOWING CONTROLLED SUBSTANCES ARE INCLUDED IN THIS
27 SCHEDULE:

28 * * *

29 (III.1) ANY COMPOUND, EXCEPT BUPROPION OR COMPOUNDS LISTED
30 UNDER A DIFFERENT SCHEDULE, OR COMPOUNDS USED WITHIN LEGITIMATE

1 AND APPROVED MEDICAL RESEARCH, STRUCTURALLY DERIVED FROM 2-
2 AMINOPROPAN-1-ONE BY SUBSTITUTION AT THE 1-POSITION WITH
3 MONOCYCLIC OR FUSED POLYCYCLIC RING SYSTEMS, WHETHER OR NOT THE
4 COMPOUND IS FURTHER MODIFIED IN ANY OF THE FOLLOWING WAYS:

5 1. BY SUBSTITUTION IN THE RING SYSTEM TO ANY EXTENT WITH
6 ALKYL, ALKYLENEDIOXY, ALKOXY, HALOALKYL, HYDROXYL OR HALIDE
7 SUBSTITUENTS WHETHER OR NOT FURTHER SUBSTITUTED IN THE RING
8 SYSTEM BY ONE OR MORE OTHER UNIVALENT SUBSTITUENTS.

9 2. BY SUBSTITUTION AT THE 3-POSITION WITH AN ACYCLIC ALKYL
10 SUBSTITUENT.

11 3. BY SUBSTITUTION AT THE 2-AMINO NITROGEN ATOM WITH ALKYL,
12 DIALKYL, BENZYL OR METHOXYBENZYL GROUPS.

13 4. BY INCLUSION OF THE 2-AMINO NITROGEN ATOM IN A CYCLIC
14 STRUCTURE.

15 * * *

16 (VII) [SYNTHETIC CANNABINOIDS OR ANY MATERIAL, COMPOUND,
17 MIXTURE OR PREPARATION WHICH CONTAINS ANY QUANTITY OF THE
18 FOLLOWING SUBSTANCES, INCLUDING THEIR ANALOGUES, CONGENERS,
19 HOMOLOGUES, ISOMERS, SALTS AND SALTS OF ANALOGUES, CONGENERS,
20 HOMOLOGUES AND ISOMERS, AS FOLLOWS:

21 1. CP 47,497 AND HOMOLOGUES, 2-[(1R,3S)-3-
22 HYDROXYCYCLOHEXYL]-5-(2-METHYLOCTAN-2-YL) PHENOL).

23 2. HU-210, [(6AR,10AR)-9-(HYDROXYMETHYL)-6,6-DIMETHYL-3-(2-
24 METHYLOCTAN-2-YL)-6A,7,10, 10A-TETRAHYDROBENZO[C] CHROMEN-1-
25 OL)].

26 3. HU-211, (DEXANABINOL, (6AS,10AS)-9-(HYDROXYMETHYL)-6,6-
27 DIMETHYL-3-(2-METHYLOCTAN-2-YL)-6A,7,10,10A-
28 TETRAHYDROBENZO[C]CHROMEN-1-OL).

29 4. JWH-018, 1-PENTYL-3-(1-NAPHTHOYL) INDOLE.

30 5. JWH-019, 1-HEXYL-3-(1-NAPHTHOYL) INDOLE.

1 6. JWH-073, 1-BUTYL-3-(1-NAPHTHOYL) INDOLE.

2 7. JWH-200, (1-(2-MORPHOLIN-4-YLETHYL) INDOL-3-YL) -
3 NAPHTHALEN-1-YLMETHANONE.

4 8. JWH-250, 1-PENTYL-3-(2-METHOXYPHENYLACETYL) INDOLE.]

5 SYNTHETIC CANNABINOIDS INCLUDING ANY MATERIAL, COMPOUND, MIXTURE
6 OR PREPARATION THAT IS NOT LISTED AS A CONTROLLED SUBSTANCE IN
7 SCHEDULE I THROUGH V, IS NOT A FEDERAL FOOD AND DRUG
8 ADMINISTRATION APPROVED DRUG OR USED WITHIN LEGITIMATE AND
9 APPROVED MEDICAL RESEARCH AND WHICH CONTAINS ANY QUANTITY OF THE
10 FOLLOWING SUBSTANCES, THEIR SALTS, ISOMERS, WHETHER OPTICAL
11 POSITIONAL OR GEOMETRIC, ANALOGUES, HOMOLOGUES AND SALTS OF
12 ISOMERS, ANALOGUES AND HOMOLOGUES, UNLESS SPECIFICALLY EXEMPTED,
13 WHENEVER THE EXISTENCE OF THESE SALTS, ISOMERS, ANALOGUES,
14 HOMOLOGUES AND SALTS OF ISOMERS, ANALOGUES AND HOMOLOGUES IF
15 POSSIBLE WITHIN THE SPECIFIC CHEMICAL DESIGNATION:

16 1. TETRAHYDROCANNABINOLS MEANING TETRAHYDROCANNABINOLS WHICH
17 ARE NATURALLY CONTAINED IN A PLANT OF THE GENUS CANNABIS AS WELL
18 AS SYNTHETIC EQUIVALENTS OF THE SUBSTANCES CONTAINED IN THE
19 PLANT OR IN THE RESINOUS EXTRACTIVES OF CANNABIS OR SYNTHETIC
20 SUBSTANCES, DERIVATIVES AND THEIR ISOMERS WITH ANALOGOUS
21 CHEMICAL STRUCTURE AND OR PHARMACOLOGICAL ACTIVITY SUCH AS THE
22 FOLLOWING:

23 (A) DELTA-1 CIS OR TRANS TETRAHYDROCANNABINOL AND THEIR
24 OPTICAL ISOMERS.

25 (B) DELTA-6 CIS OR TRANS TETRAHYDROCANNABINOL AND THEIR
26 OPTICAL ISOMERS.

27 (C) DELTA-3,4 CIS OR THEIR TRANS TETRAHYDROCANNABINOL AND
28 THEIR OPTICAL ISOMERS.

29 2. NAPHTHOYLINDOLES OR ANY COMPOUND CONTAINING A 3-(-1-
30 NAPHTHOYL) INDOLE STRUCTURE WITH SUBSTITUTION AT THE NITROGEN

1 ATOM OF THE INDOLE RING WHETHER OR NOT FURTHER SUBSTITUTED IN
2 THE INDOLE RING TO ANY EXTENT AND WHETHER OR NOT SUBSTITUTED IN
3 THE NAPHTHYL RING TO ANY EXTENT. THIS SHALL INCLUDE THE
4 FOLLOWING:

5 (A) JWH 015.

6 (B) JWH 018.

7 (C) JWH 019.

8 (D) JWH 073.

9 (E) JWH 081.

10 (F) JWH 122.

11 (G) JWH 200.

12 (H) JWH 210.

13 (I) JWH 398.

14 (J) AM 2201.

15 (K) WIN 55,212.

16 3. NAPHYLMETHYLINDOLES OR ANY COMPOUND CONTAINING A 1H-
17 INDOL-3-YL-(1-NAPHTHYL) METHANE STRUCTURE WITH A SUBSTITUTION AT
18 THE NITROGEN ATOM OF THE INDOLE RING WHETHER OR NOT FURTHER
19 SUBSTITUTED IN THE INDOLE RING TO ANY EXTENT AND WHETHER OR NOT
20 SUBSTITUTED IN THE NAPHTHYL RING TO ANY EXTENT. THIS SHALL
21 INCLUDE JWH 175 AND JWH 184.

22 4. NAPHTHOYLPYRROLES OR ANY COMPOUND CONTAINING A 3-(1-
23 NAPHTHOYL) PYRROLE STRUCTURE WITH SUBSTITUTION AT THE NITROGEN
24 ATOM OF THE PYRROLE RING WHETHER OR NOT FURTHER SUBSTITUTED IN
25 THE PYRROLE RING TO ANY EXTENT AND WHETHER OR NOT SUBSTITUTED IN
26 THE NAPHTHYL RING TO ANY EXTENT. THIS SHALL INCLUDE JWH 147 AND
27 JWH 307.

28 5. NAPHTHYLMETHYLINDENES OR ANY COMPOUND CONTAINING A
29 NAPHTHYLIDENEINDENE STRUCTURE WITH SUBSTITUTION AT THE 3-
30 POSITION OF THE INDENE RING WHETHER OR NOT FURTHER SUBSTITUTED

1 IN THE INDENE RING TO ANY EXTENT AND WHETHER OR NOT SUBSTITUTED
2 IN THE NAPHTHYL RING TO ANY EXTENT. THIS SHALL INCLUDE JWH 176.

3 6. PHENYLACETYLINDOLES OR ANY COMPOUND CONTAINING A 3-
4 PHENYLACETYLINDOLE STRUCTURE WITH SUBSTITUTION AT THE NITROGEN
5 ATOM OF THE INDOLE RING WHETHER OR NOT FURTHER SUBSTITUTED IN
6 THE INDOLE RING TO ANY EXTENT AND WHETHER OR NOT SUBSTITUTED IN
7 THE PHENYL RING TO ANY EXTENT. THIS SHALL INCLUDE THE FOLLOWING:

8 (A) RCS-8, SR-18 OR BTM-8.

9 (B) JWH 250.

10 (C) JWH 203.

11 (D) JWH 251.

12 (E) JWH 302.

13 7. CYCLOHEXYLPHENOLS OR ANY COMPOUND CONTAINING A 2-(3-
14 HYDROXYCYCLOHEXYL) PHENOL STRUCTURE WITH A SUBSTITUTION AT THE
15 5-POSITION OF THE PHENOLIC RING WHETHER OR NOT SUBSTITUTED IN
16 THE CYCLOHEXYL RING TO ANY EXTENT. THIS SHALL INCLUDE THE
17 FOLLOWING:

18 (A) CP 47,497 AND ITS HOMOLOGUES AND ANALOGS.

19 (B) CANNABICYCLOHEXANOL.

20 (C) CP 55,940.

21 8. BENZOYLINDOLES OR ANY COMPOUND CONTAINING A 3-(BENZOYL)
22 INDOLE STRUCTURE WITH SUBSTITUTION AT THE NITROGEN ATOM OF THE
23 INDOLE RING WHETHER OR NOT FURTHER SUBSTITUTED IN THE INDOLE
24 RING TO ANY EXTENT AND WHETHER OR NOT SUBSTITUTED IN THE PHENYL
25 RING TO ANY EXTENT. THIS SHALL INCLUDE THE FOLLOWING:

26 (A) AM 694.

27 (B) PRAVADOLINE WIN 48,098.

28 (C) RCS 4.

29 (D) AM 679.

30 9. [2,3-DIHYDRO-5 METHYL-3-(4-MORPHOLINYLMETHYL) PYRROLO

1 [1,2,3-DE]-1, 4-BENZOXAZIN-6-YL]-1-NAPHTHALENYMETHANONE. THIS
2 SHALL INCLUDE WIN 55,212-2.

3 10. DIBENZOPYRANS OR ANY COMPOUND CONTAINING A 11-HYDROXY-
4 DELTA 8-TETRAHYDROCANNABINOL STRUCTURE WITH SUBSTITUTION ON THE
5 3-PENTYL GROUP. THIS SHALL INCLUDE HU-210, HU-211, JWH 051 AND
6 JWH 133.

7 11. ADAMANTOYLINDOLES OR ANY COMPOUND CONTAINING A 3-(-1-
8 ADAMANTOYL) INDOLE STRUCTURE WITH SUBSTITUTION AT THE NITROGEN
9 ATOM OF THE INDOLE RING WHETHER OR NOT FURTHER SUBSTITUTED IN
10 THE ADAMANTOYL RING SYSTEM TO ANY EXTENT. THIS SHALL INCLUDE AM
11 1248.

12 12. TETRAMETHYLCYCLOPROPYLINDOLES OR ANY COMPOUND CONTAINING
13 A 3-TETRAMETHYLCYCLOPROPYLINDOLE STRUCTURE WITH SUBSTITUTION AT
14 THE NITROGEN ATOM OF THE INDOLE RING WHETHER OR NOT FURTHER
15 SUBSTITUTED IN THE INDOLE RING TO ANY EXTENT AND WHETHER OR NOT
16 SUBSTITUTED IN THE TETRAMETHYLCYCLOPROPYL RING TO ANY EXTENT.
17 THIS SHALL INCLUDE UR-144 AND XLR-11.

18 13. N-(1-ADAMANTYL)-1-PENTYL-1H-INDAZOLE-3-CARBOXAMIDE. THIS
19 SHALL INCLUDE AKB48.

20 14. ANY OTHER SYNTHETIC CHEMICAL COMPOUND THAT IS A
21 CANNABINOID RECEPTOR TYPE 1 AGONIST AS DEMONSTRATED BY BINDING
22 STUDIES AND FUNCTIONAL ASSAYS THAT IS NOT LISTED IN SCHEDULES
23 II, III, IV AND V, NOT FEDERAL FOOD AND DRUG ADMINISTRATION
24 APPROVED DRUG OR USED WITHIN LEGITIMATE, APPROVED MEDICAL
25 RESEARCH.

26 * * *

27 SECTION 2. THIS ACT SHALL TAKE EFFECT IMMEDIATELY.